IL-8 Receptor Modified Patient-Derived Activated CD70 CAR T Cell Therapy in Adults With Brain Metastases

This is a Phase I Study evaluating the safety and feasibility of IL-8 receptor-modified patient-derived activated CD70 CAR T cells in adult patients with brain metastases from primary cancer, with either newly diagnosed lesions or recurrent or progressive disease after prior therapy.

NCT Number	NCT07569263
Lead Sponsor	University of Florida
Conditions	Brain Metastases
Enrollment	12 participants
Start Date	2026-07
Primary Completion	2029-12 (estimated)
Study Completion	2044-12 (estimated)
Updated on ClinicalTrials.gov	2026-05-06